In the case of HER2, clinical imaging studies have shown that different classes of ESPs (e.g., affibody molecules, ADAPTs, DARPins) specifically and efficiently accumulate in tumors expressing the receptor, which suggest that they can potentially be suitable carriers of cytotoxic drugs for cancer therapy [6,12,13,14]. Here, ERBB2 is linked to cancer.